| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ... New England Journal of Medicine 353 (16), 1659-1672, 2005 | 6592 | 2005 |
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study AT Stopeck, A Lipton, JJ Body, GG Steger, K Tonkin, RH De Boer, ... Journal of clinical oncology 28 (35), 5132-5139, 2010 | 1879 | 2010 |
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer M Gnant, B Mlineritsch, W Schippinger, G Luschin-Ebengreuth, ... New England Journal of Medicine 360 (7), 679-691, 2009 | 1280 | 2009 |
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1081 | 2010 |
| Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli, P Rastogi, ... New England Journal of Medicine 384 (25), 2394-2405, 2021 | 991 | 2021 |
| Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial M Gnant, B Mlineritsch, H Stoeger, G Luschin-Ebengreuth, D Heck, ... The lancet oncology 12 (7), 631-641, 2011 | 593 | 2011 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial M Gnant, G Pfeiler, PC Dubsky, M Hubalek, R Greil, R Jakesz, V Wette, ... The Lancet 386 (9992), 433-443, 2015 | 583 | 2015 |
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ... The lancet oncology 14 (10), 933-942, 2013 | 509 | 2013 |
| Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases A Lipton, GG Steger, J Figueroa, C Alvarado, P Solal-Celigny, JJ Body, ... Journal of Clinical Oncology 25 (28), 4431-4437, 2007 | 462 | 2007 |
| Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal … M Gnant, M Filipits, R Greil, H Stoeger, M Rudas, Z Bago-Horvath, ... Annals of oncology 25 (2), 339-345, 2014 | 452 | 2014 |
| Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy M Gnant, B Mlineritsch, G Luschin-Ebengreuth, F Kainberger, ... The lancet oncology 9 (9), 840-849, 2008 | 448 | 2008 |
| Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade … R Jakesz, H Hausmaninger, E Kubista, M Gnant, C Menzel, ... Journal of Clinical Oncology 20 (24), 4621-4627, 2002 | 363 | 2002 |
| Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis … M Gnant, B Mlineritsch, H Stoeger, G Luschin-Ebengreuth, M Knauer, ... Annals of Oncology 26 (2), 313-320, 2015 | 339 | 2015 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 322 | 2019 |
| Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent … D Miles, A Chan, G Romieu, LY Dirix, J Cortes, X Pivot, P Tomczak, ... Journal of clinical oncology 26 (15_suppl), LBA1011-LBA1011, 2008 | 319 | 2008 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 316 | 2021 |
| High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) R Simanek, R Vormittag, C Ay, G Alguel, D Dunkler, I Schwarzinger, ... Journal of Thrombosis and Haemostasis 8 (1), 114-120, 2010 | 297 | 2010 |
| Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial M Karthaus, A Kretzschmar, H Kröning, M Biakhov, D Irwin, N Marschner, ... Annals of Oncology 17 (2), 289-296, 2006 | 272 | 2006 |
| Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial G Pfeiler, R Königsberg, C Fesl, B Mlineritsch, H Stoeger, CF Singer, ... Journal of Clinical Oncology 29 (19), 2653-2659, 2011 | 246 | 2011 |
| Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality N Pavo, M Raderer, M Hülsmann, S Neuhold, C Adlbrecht, G Strunk, ... Heart 101 (23), 1874-1880, 2015 | 239 | 2015 |
